910377-30-9Relevant academic research and scientific papers
NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
-
Page/Page column 80; 82, (2019/09/12)
The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
Copper-catalyzed benzylic C(sp3)-H alkoxylation of heterocyclic compounds
Takemura, Noriaki,Kuninobu, Yoichiro,Kanai, Motomu
supporting information, p. 2528 - 2532 (2014/04/17)
We achieved intra- and intermolecular C(sp3)-H alkoxylation of benzylic positions of heteroaromatic compounds using CuBrn (n = 1, 2)/5,6-dimethylphenanthroline (or 4,7-dimethoxyphenanthroline) and ( tBuO)2 as a
Copper-catalyzed C-H alkoxylation of azoles
Takemura, Noriaki,Kuninobu, Yoichiro,Kanai, Motomu
supporting information, p. 844 - 847 (2013/03/28)
We achieved copper-catalyzed intramolecular and intermolecular alkoxylation of azoles. This reaction is a rare example of transition-metal-catalyzed C-H alkoxylation of heteroaromatic compounds. In addition, the alkoxylation reaction proceeded well even i
BENZIMIDAZOLONE DERIVATIVES
-
Page/Page column 59, (2009/12/23)
This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective am
BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS
-
Page/Page column 71-72, (2008/06/13)
This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of suc
